PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2013; 8(7): e69333.
Published online 2013 July 25. doi:  10.1371/journal.pone.0069333
PMCID: PMC3723895

A Mutation in Mouse Pak1ip1 Causes Orofacial Clefting while Human PAK1IP1 Maps to 6p24 Translocation Breaking Points Associated with Orofacial Clefting

Li Chen, Editor

Abstract

Orofacial clefts are among the most common birth defects and result in an improper formation of the mouth or the roof of the mouth. Monosomy of the distal aspect of human chromosome 6p has been recognized as causative in congenital malformations affecting the brain and cranial skeleton including orofacial clefts. Among the genes located in this region is PAK1IP1, which encodes a nucleolar factor involved in ribosomal stress response. Here, we report the identification of a novel mouse line that carries a point mutation in the Pak1ip1 gene. Homozygous mutants show severe developmental defects of the brain and craniofacial skeleton, including a median orofacial cleft. We recovered this line of mice in a forward genetic screen and named the allele manta-ray (mray). Our findings prompted us to examine human cases of orofacial clefting for mutations in the PAK1IP1 gene or association with the locus. No deleterious variants in the PAK1IP1 gene coding region were recognized, however, we identified a borderline association effect for SNP rs494723 suggesting a possible role for the PAK1IP1 gene in human orofacial clefting.

Introduction

Among the most common birth defects are clefts of the lip and/or palate (CL/P), which affect about one in 700 births worldwide [1], [2]. Orofacial defects can be syndromic, with a variety of other clinical features, or isolated (approximately 70%) and can involve major difficulties with food intake, speech, hearing and ensuing psychological development. As a subset of orofacial clefts, median clefts are extremely rare and originate from the failure of the frontonasal processes to fuse along the midline during development. Orofacial clefts have a complex and poorly understood etiology with both genetic and environmental factors contributing. Some progress in the identification of genes implicated in CL/P disorders has occurred over the last decade, with a major contribution for new candidate genes in recent years from Genome Wide Association Studies (GWAS) [3][5]. Nevertheless, variants in these genes (e.g. IRF6, MAFB, ARGHAP29, VAX1, 8q24) do not account for all cases with genetic etiology underlining the need for identifying new genes contributing to the burden of orofacial clefts and the molecular processes they regulate [2], [6].

One chromosomal region of importance for orofacial clefts is 6p24 (orofacial cleft 1, OMIM 119530) with several studies suggesting an associated locus. Chromosomal translocation breaking points in patients with orofacial clefts have been finely mapped to 6p24.3 [7], [8]. TFAP2A lies within this region; mutations in this gene, which encodes a transcription factor, cause branchio-ocular-craniofacial syndrome, an autosomal dominant disorder that includes CL/P [9]. In addition, TFAP2A regulates through a specific binding site the expression of IRF6, causative in Van der Woude syndrome, which can include CL/P. Interestingly, this binding site contains a variant (rs642961) that disrupts TFAP2A binding and is overtransmitted in clefting patients [10]. Additional genes, distal to the translocation breaking points, include several important regulators of developmental processes such as BMP6 and several members of the FOX gene family, but none has been with certainty associated with orofacial clefts. In addition, several studies have shown linkage of CL/P syndromes to markers in 6p23 [11][14].

PAK1IP1 (Pak1 interacting protein 1), maps to 6p24.2 approximately 203 kb centromeric from OFC1. The encoded protein is also known as hPIP1 (human Pak1 Interacting Protein 1) or as the yeast homolog Skb15 (Schizosaccharomyces pombe Shk1 kinase binding protein 15) and was initially identified in two independent yeast two-hybrid screens using yeast and human Pak1 (P21-activated kinase) as bait respectively [15], [16]. P21-activated kinases (PAKs) are serine-threonine protein kinases that are positively regulated by the small GTPases, Cdc42 and Rac1 [17], [18]. In vertebrates PAKs control diverse cellular processes, including gene expression, cytoskeletal actin and tubulin assembly, neurite outgrowth, cell cycle control, and apoptosis. Pak1ip1 is largely comprised of WD40 repeats and was initially described as a negative regulator of Pak1. Interestingly, more recent research has shown that Pak1ip1 also localizes to the nucleolus where it is involved in ribosome biogenesis, in light of which its interaction with Pak1 and the cellular events it mediates through this function appear secondary [19]. By facilitating ribosomal RNA processing, Pak1ip1 plays a regulatory role in cell growth and proliferation apparently through direct interaction with the tumor protein 53 (Tp53)-murine double minute 2 (Mdm2) loop upon cellular stress [20]. Furthermore, by causing craniofacial anomalies if mutated, Pak1ip1 joins a group of molecules causative in ribosomopathies associated with craniofacial defects. They include for instance TCOF1 (Treacher-Collins-Franceschetti syndrome 1) and ribosomal proteins S19 and S24 (RPS19, RPS24) in Diamond-Blackfan anemia [21], [22].

Here, we demonstrate that Pak1ip1 is a factor required for proper craniofacial morphogenesis presumably by its unique role in ribosome biogenesis, further adding to our understanding of craniofacial morphology and its underlying molecular regulation.

Results

manta-ray, a novel mouse line with orofacial clefting

In a forward genetic screen aimed at identifying mutations affecting neural development in mice [23], we recovered a mutant line with wide-ranging defects including median orofacial clefting. The mutation displayed autosomal-recessive inheritance and we named the line manta-ray (mray) due to the pathological morphology resulting from the clefting of the maxillae and secondary palate of the homozygous mutants (figure 1). At embryonic day (E)14.5 the palatal shelves of homozygous mutants elevate but fail to meet and fuse at the midline. Midline structures of the frontonasal skeleton, such as the nasal septum are severely reduced. Brain defects included a considerably smaller forebrain and hindbrain, which in part can be attributed to smaller ventricles (figure 1 and data not shown) but a relatively enlarged midbrain. In addition, most affected mutants are overall smaller at all stages, appear developmentally delayed, and a subcutaneous edema, possibly due to a heart and/or lymphatic defect, covers almost the entirety of the body (figure 2). The hypoplasia of craniofacial structures affects also the developing musculature as a comparison between the masseter muscles of wild-type and homozygous mutants demonstrates (figure 2). While mray homozygous mutants die as embryos, usually at around 14 days of gestation, heterozygotes appear phenotypically unaffected, are fertile, and have a normal lifespan.

Figure 1
Homozygous mray mutants show severe craniofacial malformations starting early in development.
Figure 2
Midline clefting and reduced growth in mray/mray mutants.

Employing microsatellite-based positional mapping and scoring more than 1500 meioses from separate crosses (heterozygote carriers, affected, and non-affected embryos), we confined the mray mutation to a 3.75 Mb-interval on chromosome 13 between markers D13Mit177 and D13Mit63 containing 20 protein-coding genes (list in figure 3). We sequenced all coding sequences in these genes and identified only one base pair substitution (C to T transition) in the Pak1ip1 gene not present in the parental strains (C57BL/6J and FVB/NJ). The mutation leads to the substitution of a single amino acid residue from a histidine to a tyrosine in an entirely conserved position of the protein as sequence alignments of all known orthologs show (figure 3 and data not shown). Consequently, the mray allele presents the first mutant Pak1ip1 allele described in mice, rendering this mouse line a very valuable model to study the effects of Pak1ip1 inactivation in vivo.

Figure 3
Positional mapping and identification of the causative mutation in the Pak1ip1 gene.

Expression of Pak1ip1 and midfacial specification in affected manta-ray mutants

To better assess the role of Pak1ip1 during development and identify clues as to how its inactivation may result in developmental defects, we observe in affected mray embryos, we examined its expression during various embryonic stages. We conducted RNA in situ hybridization analysis on whole-mount embryos and sections of embryonic tissue. Our results show that Pakip1 is widely expressed in the embryo, consistent with its role in ribosome biogenesis on which every cell depends. Specifically, Pak1ip1 is expressed throughout the embryo with somewhat higher levels of expression in forebrain, facial primordia, limb buds, and liver (figure 4). Interestingly, the higher expression levels of Pak1ip1 in forebrain, facial structures, and liver, correspond to some of the most severely affected areas of the mray/mray embryos. These findings may point towards a particularly important role for Pak1ip1 expression levels in the histogenesis of certain organs.

Figure 4
Developmental expression of the Pak1ip1 gene.

Pak1ip1 has been implicated in the regulation of both cytoskeletal regulation through the inhibition of the serine/threonine kinase Pak1 [15], [16] and ribosome biogenesis [19], [20]. The multiple and complex cellular functions Pak1ip1 may mediate, presents a challenge in understanding the molecular and cellular mechanisms underlying the median cleft in the mray/mray animals. To explain the midline cleft in homozygous mutants, we first considered local effects such as a specific deficit in patterning and specification of midfacial structures during development. During midgestational stages (E8.5 – E10) the frontonasal process, which will give rise to midfacial structures, is characterized by the expression of several factors that exert proliferative activity and are critical for proper outgrowth. Of particular relevance in this context are members of the fibroblast growth factor (Fgf) family and sonic hedgehog (Shh) [24][26]. Interestingly, Pak1 has been shown in a recent study to participate in the Fgf signaling pathway, which also interacts with the Shh pathway [27]. To examine possible changes in the expression of genes required to form the medial face we carried out whole-mount RNA in situ hybridization for Fgf8, Fgf17, and Shh on wild-type, heterozygotes, and mutants. Analyzing stages E9.0 to E11.5 (figure 5 and data not shown), we detected only mild changes in expression levels and distribution of these molecular markers but largely intact expression domains. Specifically, at E9.5 the midfacial expression domains of Fgf8 and Fgf17 largely overlapped with the frontonasal prominence and formed bilateral stripes around the midline, irrespective of genotype. Some low-level variation in the size of the expression domains, we attributed to size differences between wild-type and mray/mray embryos. Shh displayed a similar, but ventrally shifted, expression pattern, which was slightly diminished in the mutant compared to the wild-type but correlated well with the overall smaller size of the mutant embryos. Overall, our results suggested, if any, a minor contribution of midfacial molecular patterning to the manifestation of midline clefting in homozygous mray mutants.

Figure 5
Midfacial specification in mray/mray embryos shows only mild changes compared to wild-type littermates.

Subcellular localization of Pak1ip1 and Tp53 regulation

The phenotype of homozygous mray carriers has a complex and pleiotropic nature, which affects many organs and tissues without interfering with their initial development. In previous studies, Pak1ip1 has been shown to localize to the nucleolus and participate in ribosome biogenesis [19], [20]. Indeed, the overall reduction in size of homozygous mray mutants could be well explained by a general deficit in protein biosynthesis resulting in a prolonged cell cycle or even cell cycle arrest and reduced growth. To obtain further insight into the function of Pak1ip1 and its possible deregulation in the mray mutant, we examined its intracellular distribution in cells derived from wild-type and affected embryos. Primary cultures of fibroblasts obtained from E13.5 day old embryos were labeled with α-Pak1ip1 and α-nucleolin antibodies. Our results confirmed an exclusive localization of Pak1ip1 to the nucleolus, completely overlapping with nucleolin immunoreactivity (figure 6). Interestingly, we did not see any apparent differences in expression levels or subcellular distribution of Pak1ip1 between wild-type and mutant cells, suggesting that even though the mray allele disrupts the function of Pak1ip1 it does not affect its localization in the cell.

Figure 6
Pak1ip1 localizes to the nucleolus and its mutation increases Tp53 levels.

A recent study by Yu et al. identified a regulatory role for Pak1ip1 in cell growth and proliferation, via direct interaction with the tumor protein 53 (Tp53)-murine double minute 2 (Mdm2) loop upon detection of cellular stress [20]. Specifically, Pak1ip1 can either induce the Tp53-Mdm2 loop indirectly by activating the Mdm2-binding ribosomal proteins Rpl5 and Rpl11 that act as nucleolar stress signals or directly by binding and inhibiting the ability of Mdm2 to ubiquitinate Tp53. Consequently, knockdown of Pak1ip1 in cell culture has been shown to cause a decrease in proliferation by inducing Tp53 dependent G1 cell cycle arrest. In order to determine if the developmental defects seen in the mray/mray mice are indeed caused by deregulation of the Tp53 pathway, we performed a western blot analysis to compare Tp53 protein levels between wild-type and mray/mray embryos at E10.5 (Figure 6). We found Tp53 levels to be significantly twofold increased in the mutant further supporting the notion that the ribosomal function of Pak1ip1 and the associated upregulation of Tp53 in the homozygous mray mutants as being instrumental in the manifestation of the craniofacial anomalies we see in this line of mice.

To further uncover the mechanism by which mutant Pak1ip1 causes an upregulation in Tp53 levels, we examined its interaction with Mdm2 using co-immunoprecipitation (Co-IP) analysis. Total lysates from whole E13.5 embryos were immunoprecipitated using a Mdm2 antibody and probed with a Pak1ip1 antibody, which did not detect any differential binding between mutant (H122Y) and wild-type Pak1ip1 protein to Mdm2 (figure 6, I). This is in support of the notion that increased Tp53 levels in the mray/mray mutants are caused by aberrant ribosome biogenesis and increased nucleolar stress due to faulty or insufficient levels of translation. In summary, we conclude that the mray allele does neither interfere with the subcellular localization of Pak1ip1 nor with its ability to interact with Mdm2 but apparently causes defects in ribosome biogenesis that elicit a nucleolar stress response with associated Tp53 upregulation.

Reduced proliferation rates of mray/mray cells can be rescued by Tp53 inhibition

Since Tp53 protein levels are elevated in mutant embryos with possible G1 cell cycle arrest, we sought to examine whether this leads also to a reduction in the rate of cell proliferation within developing craniofacial structures, as expected. We decided to count mitotic cells within the palatal shelves at stage E13.5 prior to their elevation since they present confined structures facilitating sampling. Consistent with our hypothesis, the palatal shelves of homozygous mray mutant embryos show a significant decrease in the ratio of phosphorylated histone-H3 immunoreactive cells compared to the palatal shelves of wild-type animals (figure 7, A–C). Since this loss of proliferative activity in mutant cells is likely caused by higher Tp53 levels, we examined whether Tp53 inhibition has the capacity to rescue the decreased proliferation rate. To that effect, we isolated facial fibroblasts from E13.5 wild-type and mutant embryos and cultured them with or without the Tp53-specific inhibitor pifithrin-α (PFT-α). Proliferation rates were assessed by Click-iT EdU cell proliferation assays utilizing incorporation and detection of the modified nucleoside, EdU (5-ethynyl-2′-deoxyuridine) in dividing cells. Comparing the ratio of dividing over non-dividing cells within a two-hour interval, we identified a substantial reduction in mitotic cells in the mutant (figure 7, D–H). Administration of 2.2 mg/ml of PFT-α in the culture media of wild-type and mutant cells lead to a significant increase in the proliferation rate of mutant cells but had no significant effect on wild-type cells compared to controls. Overall, inhibition of Tp53 using PFT-α increased proliferation levels of mray/mray cells to levels comparable to their wild-type counterparts.

Figure 7
Proliferation deficits in mray/mray embryos can be rescued in vitro by Tp53 inhibition.

PAK1IP1 association and sequencing studies

Next we examined the possibility that PAK1IP1 (6p24.2) may be a human disease gene as was suggested by studies that mapped translocation breaking points associated with cleft lip and palate to human chromosome 6p24.1 [7], [8]. PAK1IP1 maps at a distance of less than 1 to these breaking points hinting at a possible role as disease gene or contributing factor to the manifestation of the craniofacial pathology in these patients (figure 8). To examine this possibility, we conducted sequencing and association studies on a set of samples obtained from 271 Filipino non-syndromic cleft lip and palate patients and their respective parents. First, we established a Hapmap haplotype block for the PAK1IP1 region looking for SNPs with a minor allele frequency (MAF) of at least 0.2 in the Chinese (CHB) and Japanese (JPT) populations. PAK1IP1 spans 14.78 kb and does not contain SNPs with a MAF higher than 0.15 for these populations. We then proceeded to expand the search for informative SNPs to 100 kb around the gene and selected 3 SNPs to genotype: rs4712827, rs521417, and rs494723, marked with boxes in the plot in figure 8. Our association analysis showed that marker rs494723 was significantly associated with CL/P cases (p = 0.01; tables 1 and and2).2). A genome-wide association study reported a SNP about 1 Mb from PAK1IP1 that reached a p value of 5.50 E-05 (rs760788) [3]. In addition, we conducted a case-control analysis in 259 Polish cases and 493 unrelated Polish controls. Results are listed in tables 3 and and4;4; similarly to our Filipino trio association results only rs494723 showed borderline significance (p = 0.0437).

Figure 8
Mouse/Human synteny and Haploview output showing linkage disequilibrium relationships of the analyzed SNPs.
Table 1
Family association results.
Table 2
Results of the haplotype analysis of the selected SNPs in the family-based association study.
Table 3
Case-control association results.
Table 4
Results of the haplotype analysis of the selected SNPs in the case-control study.

We proceeded to sequence the 10 exons of PAK1P1 in samples obtained from 271 Filipino non-syndromic cleft lip and palate patients. We identified 3 not previously reported noncoding variants, an A/C change at chr6:10,695,513 was found in 4 patients while chr6:10,707,487 (A/T) and chr6:10,707,787 (A/G) was only found in one patient each. These variants are considered new since they are not present in public databases, which include over 7,000 individually sequenced whole exomes [28], [29]. However, no unambiguously deleterious mutations were identified with this approach.

Discussion

The Centers for Disease Control estimate that orofacial clefts with an average worldwide rate of 1 to 700 are the most common birth defects. Consequently, the search for genetic factors causing these defects is a high priority in addressing diagnostic, preventive, and therapeutic needs for orofacial clefts [30]. In a forward genetic screen in mice, we identified a mutation in the Pak1ip1 gene that causes a median cleft with cleft palate in homozygous mutants. These animals present us with the first described mutant allele of the Pak1ip1 gene in mice. Pak1ip1 is a molecule of approximately 50 kDa almost entirely comprised of five WD40 repeats, which have been characterized as sites of protein-protein interaction to which proteins can bind either stably or reversibly to form larger assemblies. The structural characteristics of Pak1ip1 indicate that it has a multitude of distinct molecular interactions underlining its complex role in cellular function. Originally, it was described as a negative regulator of the serine-threonine kinase Pak1 (P21-activated kinase) thus mediating processes of gene expression, cytoskeletal actin and tubulin assembly, cell cycle control, and apoptosis [15], [16]. Subsequent studies have shown that next to its presumed function in cytoskeletal regulation, Pak1ip1 also localizes to the nucleolus where it is involved in ribosome biogenesis, specifically the assembly of the 60S ribosomal subunit [19]. As a preribosomal factor, Pak1ip1 facilitates ribosomal RNA processing and plays a regulatory role in cell growth and proliferation, apparently through direct interaction with the tumor protein 53 (Tp53)-murine double minute 2 (Mdm2) loop upon cellular stress [20]. Its function suggests impairment in ribosome biogenesis as the underlying cause of the observed craniofacial defects in Pak1ip1mray/mray mutants, which is also supported by our findings. Specifically, we identified both an exclusive localization of Pak1ip1 to the nucleolus and an upregulation of Tp53 levels in homozygous mray embryos during the early formation of craniofacial structures (figure 6), consistent with the notion that cellular stress causes Tp53-dependent G1 cell-cycle arrest associated with the reduced outgrowth of midfacial structures. Furthermore, we found the rate of proliferation within the developing palatal shelves of the mutants to be significantly decreased and pharmacological inhibition of Tp53 with pifithrin-α in primary facial fibroblasts was able to rescue this proliferative deficit in vitro. Interestingly, the mray allele neither interferes with the nucleolar localization of mutant Pak1ip1H122Y, which is expected since its nuclear and nucleolar localization signals were previously mapped to the C-terminus of the protein (corresponding to amino acid residues 366–382 in mouse) [20], nor with its affinity to the Tp53 regulator Mdm2. Yu et al. proposed two mechanisms by which Pakip1 can elicit an upregulation of Tp53 levels resulting in cell cycle arrest. First, by overexpression and direct inhibition of Mdm2 inhibiting its ability to ubiquitinate and degrade Tp53 and second, indirectly after knockdown, by increasing the concentration of free ribosomal proteins L5 and L11, which also bind to and inhibit Mdm2. In Mdm2-Pak1ip1 co-immunoprecipitation experiments using either wild-type or mutant lysates, we did not detect any differences between genotypes strongly suggesting the mray allele as a loss-of-function mutation disabling the proper participation of the mutant protein in ribosome biogenesis. We also examined a possible local, midfacial deregulation of signaling molecules important for midfacial outgrowth such as Fgf8, Fgf17, and Shh, but detected only mild changes in the craniofacial expression of these genes. It is very unlikely that low-level changes in the midfacial expression of these genes causes the midline defects seen in homozygous mray mutants, particularly in light of a recent study by Griffin et al., which found that a loss of approximately 80% of Fgf8 expression in Fgf8null/neo mice is required to cause a midfacial cleft of comparable extent to the cleft in the Pak1ip1mray/mray mutants [31]. Overall, our findings are consistent with the hypothesis that aberrant ribosome biogenesis associated with cell cycle arrest caused by increased Tp53 activity is the major mechanism underlying the craniofacial hypoplasia displayed by homozygous mray mutants.

Pathological changes of a similar nature to the mray/mray phenotype can be seen in human ribosomopathies such as Diamond-Blackfan anemia (DBA) or Treacher Collins syndrome (TCS), which are associated with craniofacial malformations including cleft palate [32], [33]. Further, in a recent study in Tail short (Ts) mice, which are characterized by a partially penetrant midfacial cleft of very similar appearance to the phenotype seen in homozygous mray mutants, causative mutations were identified in the gene encoding the ribosomal protein L38 (Rpl38) [34]. Interestingly, in mice carrying mutations in the Tcof gene, a successful rescue of the mutant craniofacial phenotype was achieved by both pharmacological and genetic inhibition of Tp53. Taken together with the results we present here, we suspect that in future studies a similar rescue may be possible for the mray/mray mutant mice too.

While orofacial clefts are very common birth defects, median clefts such as the one displayed by the Pak1ip1mray/mray animals are extremely rare. Median clefts arise from the failure of the frontonasal processes to fuse along the midline during development. To this date no causative mutation for isolated midline clefting in humans has been identified but midline clefts are commonly seen in holoprosencephaly syndromes for which several genes have been identified. In addition, a few genetically defined mouse models exist. These include compound mutants of the (Alx4//Cart1+/) [35], retinoic acid receptors and α and γ double mutants (Rarα//Rarγ/) [36], and platelet-derived growth factor receptor mutants (Pdgfrαph/ph, Pdgfrα/) [37], [38]. In Tail short (Ts) mice, which show with partial penetrance a midfacial cleft, causative mutations were identified in the gene encoding the ribosomal protein L38 (Rpl38) [34]. This finding may point to a more general role for ribosome biogenesis defects and associated deficits in protein biosynthesis as an underlying cause for median clefts.

The possible role for PAK1IP1 (6p24.2) in human disease was suggested by studies mapping translocation breaking points associated with cleft lip and palate in affected individuals to human chromosome 6p24.1 [7], [8]. PAK1IP1 maps between 0.5 and 1 Mb of these breaking points making it a possible candidate or contributing factor to the manifestation of the disease phenotype in these patients. To examine this possibility, we conducted sequencing and association studies. While our results did not provide clear evidence associating PAK1P1 with orofacial clefts, some association was seen for the nearby marker rs494723 and for a haplotype (Table 1).

Several factors may explain the fact that we did not find a mutation within the coding sequences of PAK1IP1. First, as for the mray allele, prenatal lethality of human carriers may eliminate them from the general and our sample population. Second, none of the samples tested was derived from a patient with the specific pathological features seen in the Pak1ip1mray/mray mutants, a median orofacial cleft with cleft palate. Third, we only sequenced the PAK1IP1 coding region in the Filipino samples since Schultz et al. have demonstrated linkage to a neighboring region (6p23) in this population [11]; however,it remains possible that etiologic variants are harbored in non-coding regulatory elements. Future studies can utilize different sample sets, particularly sets that include samples from patients with median clefts and relevant neuronal defects as well as populations of different genetic background. In summary, our findings point towards an important role for Pak1ip1 as a developmental regulator, particularly in the formation of the cranial skeleton, but require further study to understand its disease relevance in the manifestation of congenital craniofacial malformations.

Materials and Methods

Ethics statement

The study was approved by the University of Iowa Institutional Review Board (IRB) in the United States under IRB-01 ID #199804080; Title: Studies of Genes Involved in Human Head, Face and Eye Disorders. Informed written consent was obtained from all participating individuals or legal caretakers and the data were analyzed anonymously. Filipino cases were recruited through ongoing follow-ups of families originally identified during Operation Smile medical missions and all practices were approved by the Internal Review Board of the Corazon Locsin Montelibano Memorial Regional Hospital [39]. Polish case eligibility was ascertained by clinicians using detailed diagnostic information from medical records and following guidelines established by the Medical Ethics Committee of the Supreme Medical Council of the Polish Chamber of Physicians and Dentists (PCHPD). The study was approved by the ethical committee of the Poznan University of Medical Sciences. Written and oral consent was obtained from all participants. Mice were housed in specific-pathogen-free facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care International (AALAC). All animals were handled in accordance with protocols approved by the University of California at Davis Institutional Animal Care and Use Committee.

Animal husbandry and genotyping

The colony of animals carrying the Pak1ip1mray allele (induced on C57BL/6J background) is maintained by crossing male carriers with FVB/NJ females. This mode of outcross is currently in the ninth generation without any changes in penetrance or variability of the mutant phenotype. All embryos presented in the phenotypic analysis of this study were produced from carriers crossed for at least four generations onto an FVB/NJ background. Routine genotyping was performed by amplifying microsatellites D13Mit63 and D13Mit177.

Positional mapping and candidate gene sequencing

The mray line was recovered in a genetic screen for recessive mutations disrupting forebrain development [23]. Positional mapping was performed using simple-sequence length polymorphic markers available from the Whitehead Institute for Biomedical Research, MIT. Initial linkage was established after a genome-wide scan using 82 simple sequence repeat markers on 12 DNA samples from both carriers and mutant embryos. For high-resolution meiotic mapping, we scored separate crosses resulting in over 1572 generated meioses (carriers and embryos counted). Using this approach, we located the mray mutation to an interval on chromosome 13 between markers D13Mit177 (38.975 Mb) and D13Mit63 (42.709 Mb) in the NCBI mouse assembly (Build 37.2, current assembly). The identified genetic interval contained 22 protein-coding genes of which all exons were amplified and sequenced from genomic DNA samples. For every set of primers, we used samples of the two parental strains (C57BL/6J and FVB/NJ) and two samples of affected mutants. All primer sequences are available upon request. Sequence comparisons were carried out using Mutation Surveyor® DNA variant analysis software (SoftGenetics, LLC, State College, PA) and BLAST (National Center for Biotechnology Information). Sequences of insufficient quality or read length were dismissed from any comparisons and repeated with revised primer sets. To further confirm that the mutation in Pak1ip1 is causative, we genotyped a total of 116 phenotypically mutant embryos (232 meioses) of stages E11.5 to E14.5, which are easy to score. For genotype analysis, we used a restriction length polymorphism created by the manta-ray allele (additional HindIII site) and found that all affected embryos carried the mutant variant in a homozygous state.

Embryo imaging and histology

Embryos of all developmental stages analyzed, were recovered after timed pregnancies and fixed by immersion in 4% paraformaldehyde in phosphate buffered saline (PBS). For some whole-mount imaging, embryos were stained with ethydium bromide at 10 μg/ml in PBS for several hours, briefly washed with several exchanges of PBS, and photographed under fluorescent illumination. Nissl stained (cresyl violet) or hematoxylin and eosin stained histological sections of 10 μm thickness were prepared from paraffin-embedded tissue using standard procedures. All RNA in situ hybridization on whole-mount embryos and sections was performed using standard procedures as previously described [40]. For each marker and developmental stage shown, we analyzed per experiment at least three embryos of each genotype (wild-type, heterozygote, mutant) and carried out every experiment at least twice. The Pak1ip1 riboprobe was transcribed from a 1.1 kb cDNA fragment containing the entire coding region of the gene (base pairs 321–1469 in NM_026550). Plasmids to transcribe riboprobes for Fgf8, Fgf17, and Shh were kindly provided by Dr. John L.R. Rubenstein.

Immunocytochemistry and immunohistochemistry

Primary fibroblasts were isolated from the facial mesenchyme of E13.5 embryos. Upon removal from the uterus, embryos were placed into ice-cold HBSS where the facial mesenchymal tissue was then isolated. The tissue was treated with DNase and trypsin-EDTA for 13 minutes at 37°C, the dissociated cells resuspended in Dulbecco's Modified Eagle Medium (DMEM), and plated on poly-D-lysine coated Lab-Tek chamber slides (Nunc, Rochester, NY). After incubation for at least 24 h cells were fixed in ice cold 4% PFA in PBS (pH 7.4) for 15 minutes prior to being permeabilized using PBS +0.25% Triton X-100. After blocking in 1% BSA (in 1× PBS +0.1% Tween-20) for one hour the cells were incubated in primary antibodies for Pak1ip1 (1[ratio]400; Orbigen, San Diego, CA) and nucleolin (1[ratio]1000; AbCam, Cambridge, MA). Cells were washed with PBS and incubated with the appropriate secondary antibodies (CY3, 1[ratio]250 and 488M 1[ratio]1000) in 1% BSA in PBS (Alexa Fluor, Invitrogen, Carlsbad, CA). Prior to the final PBS rinse, cells were counterstained with the fluorescent nucleic acid stain 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA), coverslipped, and imaged using a Nikon scanning confocal laser microscope with the associated proprietary software (Nikon Instruments, Tokyo). Phospho-histone H3 immunofluorescent analysis was carried out on 14 mounted sections cut from tissue fixed in 4% paraformaldehyde/PBS and cryoprotectively frozen in 30% sucrose using an α-pHH3 antibody (1[ratio]400, Abcam, Cambridge, MA). Same buffers and incubations were used as described above.

Western analysis

25 μg of protein lysates obtained from whole E10.5 embryos were run on a Nu-Page 4–12% Bis-Tris gels (Invitrogen, Carlsbad, CA). Proteins were transferred to nitrocellulose membranes and blocked in Odyssey blocking buffer (Li-Cor Biosciences, Lincoln, NE). Membranes were incubated with Tp53 primary antibody (1[ratio],000; Cell Signaling Technology, Boston, MA) diluted in Odyssey blocking buffer +0.1% Tween-20, overnight at 4°C. After washing, we incubated with Li-Cor IR secondary antibody (1[ratio]15,000; Li-Cor Biosciences, Lincoln, NE) in Odyssey blocking buffer +0.1% Tween-20, washed, and imaged on the Li-Cor Odyssey IR scanner. The process was repeated with β-actin as loading control (Novus Biologicals, Littleton, CO). Protein sizes were assigned using the Li-Cor infrared two-color protein marker. Signal intensity relative to background was determined using Li-Cor Image Studio version 2.0 software and Prism version 6 software was used to calculate standard error and perform a t-test in order to assign statistical significance to the results (GraphPad Software, La Jolla, CA).

Co-immunoprecipitation analysis

All experiments were conducted in triplicate using components of the Immunoprecipitation Kit – Dynabeads Protein G from Invitrogen (Carlsbad, CA). 1 mg of whole embryo (E13.5) protein lysate from wild-type and mray/mray animals was incubated with 10 μg of Mdm2 antibody (Abcam, Cambridge, MA) and 200 μl of antibody binding buffer overnight on a rocker at 4°C. Subsequently, 50 μl of protein-G dynabeads were added to the mixture, and incubated on a rocker at 4°C for 2.5 hours. Following this step, the bead-antibody-protein complex was washed thrice with 200 μl of wash buffer before being suspended in 30 μl of a 70% 4× LDS and 30% 10× reducing agent solution. The samples were then boiled for 10 minutes at 70°C prior to being loaded (15 ul) onto a 4–12% bis-tris gel (Invitrogen). Western analysis was carried out as described above exposing the membrane to 1 μg/ml of Pak1ip1 antibody (Orbigen, San Diego, CA) for 12 hours at 4°C.

EdU proliferation assay

Primary facial fibroblast cells from wild-type and homozygous manta-ray mutants were cultured in DMEM growth media on 4-chambered culture slides (Nunc, Rochester, NY) for 24 hours with or without 2.2 μg/ml of the Tp53 inhibitor pifithrin-α (Sigma) and then exposed to 10 μM 5-ethynyl-2'-deoxyuridine (EdU, Invitrogen, Carlsbad, CA) for two hours at 37°C. Subsequently, cells were fixed in 4% paraformaldehyde in PBS prior to click chemistry development of EdU and DAPI staining. For the quantification of EDU+ and DAPI+ cells, a total of five randomly selected independent fields (600×600 μm) between three slides for each experimental group were analyzed. Each field contained approximately 100 cells. Statistical significance was assigned using a two-tailed Student's t-test with Prism version 6 software (GraphPad Software, La Jolla, CA).

Human subjects

Two hundred and fifty nine NSCL/P patients (228 cases with cleft lip and palate and 31 cases with cleft lip only) were identified from the Department of Pediatrics and Pediatric Surgery at the Institute of Mother and Child in Warsaw as well as from the University Clinic of the Medical Academy in Wroclaw and the Department of Plastic Surgery Specialist Medical Center in Polanica Zdroj. The control group was composed of 493 healthy individuals with no family history of clefts or other major congenital anomalies. Controls were matched with the NSCL/P patients for age, sex and the place of residence. Peripheral blood samples were obtained from selected individuals in both populations and DNA was extracted.

Association study

Single nucleotide polymorphisms (SNPs) were selected using the Hapmap Project and Haploview tagged SNPs for the Chinese and Japanese population, restricting minor allele frequencies to 0.2 and selecting enough SNPs to provide at least 80% genetic coverage of haplotype blocks [41]. Selected SNPs (Table 1) were genotyped by allelic discrimination using Taqman assays (Applied Biosystems, Foster City, CA, USA) in 307 Filipino trios consisting of a nonsyndromic CL/P patient and both parents. Association was assessed using Familiy Based Association Test (FBAT) [42].

Case-control Study

The same SNPs as in the association study were genotyped by high-resolution melting curve analysis (HRM) on the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany) in a set of 259 nonsyndromic CL/P cases and 493 unaffected controls. The differences in allele and genotype frequencies between case and control mothers were determined using Chi-square test. SNPs were tested for association with NSCL/P using the Cochran-Armitage trend test. The strength of association was estimated by Odds Ratio (OR) and a corresponding 95% confidence interval (95%CI). Both recessive and dominant inheritance models were analysed. A p-value < 0.05 was considered statistically significant. Haplotype based association analysis was performed using the UNPHASED 3.1.5 program with the following analysis options: all window sizes, full model and uncertain haplotype option. Haplotypes with a frequency below 0.01 were set to zero [43]. Significant p-values were corrected using the 1000-fold permutation test.

Direct sequencing

The PAK1IP1 coding region was sequenced in 273 Filipino nonsyndromic CL/P patients. Primers were designed using primer3 and are available upon request [44]. Templates for sequencing were generated by PCR in an Applied Biosystems Gene Amp PCR System 9700, as described in Mansilla et al. [45]. Sequencing reactions were resolved on an ABI Prism 3700 analyzer and analyzed by Polyphred 4.0 and Consed.

Acknowledgments

We thank all the subjects as well as the attendant nursing staff, technical advisers and other coworkers involved for their participation in this study. We would like to thank Xiaoyn Qin and Jennifer Standley for assistance in genotyping and sequencing respectively. We also wish to thank Drs. Ralph Marcucio, Paul Trainor, Ophir Klein, and Chengji Zhou for helpful discussions during the course of this project.

Funding Statement

This work was in part supported by Shriners Hospitals for Children (KSZ) and National Institutes of Health grant NIH DE08559 (JCM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Murray JC (2002) Gene/environment causes of cleft lip and/or palate. Clin Genet 61: 248–256. [PubMed]
2. Dixon MJ, Marazita ML, Beaty TH, Murray JC (2011) Cleft lip and palate: understanding genetic and environmental influences. Nat Rev Genet 12: 167–178. [PMC free article] [PubMed]
3. Beaty TH, Murray JC, Marazita ML, Munger RG, Ruczinski I, et al. (2010) A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet 42: 525–529. [PMC free article] [PubMed]
4. Birnbaum S, Ludwig KU, Reutter H, Herms S, Steffens M, et al. (2009) Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. Nat Genet 41: 473–477. [PubMed]
5. Mangold E, Ludwig KU, Birnbaum S, Baluardo C, Ferrian M, et al. (2010) Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. Nat Genet 42: 24–26. [PubMed]
6. Jugessur A, Murray JC (2005) Orofacial clefting: recent insights into a complex trait. Curr Opin Genet Dev 15: 270–278. [PMC free article] [PubMed]
7. Davies AF, Stephens RJ, Olavesen MG, Heather L, Dixon MJ, et al. (1995) Evidence of a locus for orofacial clefting on human chromosome 6p24 and STS content map of the region. Hum Mol Genet 4: 121–128. [PubMed]
8. Davies SJ, Wise C, Venkatesh B, Mirza G, Jefferson A, et al. (2004) Mapping of three translocation breakpoints associated with orofacial clefting within 6p24 and identification of new transcripts within the region. Cytogenet Genome Res 105: 47–53. [PubMed]
9. Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, et al. (2008) TFAP2A mutations result in branchio-oculo-facial syndrome. Am J Hum Genet 82: 1171–1177. [PubMed]
10. Rahimov F, Marazita ML, Visel A, Cooper ME, Hitchler MJ, et al. (2008) Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet 40: 1341–1347. [PMC free article] [PubMed]
11. Schultz RE, Cooper ME, Daack-Hirsch S, Shi M, Nepomucena B, et al. (2004) Targeted scan of fifteen regions for nonsyndromic cleft lip and palate in Filipino families. Am J Med Genet A 125A: 17–22. [PubMed]
12. Scapoli L, Pezzetti F, Carinci F, Martinelli M, Carinci P, et al. (1997) Evidence of linkage to 6p23 and genetic heterogeneity in nonsyndromic cleft lip with or without cleft palate. Genomics 43: 216–220. [PubMed]
13. Prescott N, Lees M, Winter R, Malcolm S (2000) Identification of susceptibility loci for nonsyndromic cleft lip with or without cleft palate in a two stage genome scan of affected sib-pairs. hum genet 106: 345–350. [PubMed]
14. Moreno LM, Arcos-Burgos M, Marazita ML, Krahn K, Maher BS, et al. (2004) Genetic analysis of candidate loci in non-syndromic cleft lip families from Antioquia-Colombia and Ohio. Am J Med Genet A 125A: 135–144. [PubMed]
15. Kim HW, Yang P, Qyang Y, Lai H, Du H, et al. (2001) Genetic and molecular characterization of Skb15, a highly conserved inhibitor of the fission yeast PAK, Shk1. Mol Cell 7: 1095–1101. [PubMed]
16. Xia C, Ma W, Stafford LJ, Marcus S, Xiong WC, et al. (2001) Regulation of the p21-activated kinase (PAK) by a human Gbeta -like WD-repeat protein, hPIP1. Proc Natl Acad Sci U S A 98: 6174–6179. [PubMed]
17. Parrini MC, Matsuda M, de Gunzburg J (2005) Spatiotemporal regulation of the Pak1 kinase. Biochem Soc Trans 33: 646–648. [PubMed]
18. Hofmann C, Shepelev M, Chernoff J (2004) The genetics of Pak. J Cell Sci 117: 4343–4354. [PubMed]
19. Saveanu C, Rousselle JC, Lenormand P, Namane A, Jacquier A, et al. (2007) The p21-activated protein kinase inhibitor Skb15 and its budding yeast homologue are 60S ribosome assembly factors. Mol Cell Biol 27: 2897–2909. [PMC free article] [PubMed]
20. Yu W, Qiu Z, Gao N, Wang L, Cui H, et al. (2011) PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53-MDM2 loop. Nucleic Acids Res 39: 2234–2248. [PMC free article] [PubMed]
21. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, et al. (1999) The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 21: 169–175. [PubMed]
22. Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, et al. (2006) Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet 79: 1110–1118. [PubMed]
23. Zarbalis K, May SR, Shen Y, Ekker M, Rubenstein JL, et al. (2004) A focused and efficient genetic screening strategy in the mouse: identification of mutations that disrupt cortical development. PLoS Biol 2: E219. [PMC free article] [PubMed]
24. Bachler M, Neubuser A (2001) Expression of members of the Fgf family and their receptors during midfacial development. Mech Dev 100: 313–316. [PubMed]
25. Wang Y, Song L, Zhou CJ (2011) The canonical Wnt/beta-catenin signaling pathway regulates Fgf signaling for early facial development. Dev Biol 349: 250–260. [PubMed]
26. Hu D, Marcucio RS (2009) A SHH-responsive signaling center in the forebrain regulates craniofacial morphogenesis via the facial ectoderm. Development 136: 107–116. [PubMed]
27. Jean S, Tremblay MG, Herdman C, Guillou F, Moss T (2012) The endocytic adapter E-Syt2 recruits the p21 GTPase activated kinase PAK1 to mediate actin dynamics and FGF signalling. Biol Open 1: 731–738. [PMC free article] [PubMed]
28. The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061–1073. [PMC free article] [PubMed]
29. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996–1006. [PubMed]
30. Lidral AC, Murray JC (2004) Genetic approaches to identify disease genes for birth defects with cleft lip/palate as a model. Birth Defects Res A Clin Mol Teratol 70: 893–901. [PubMed]
31. Griffin JN, Compagnucci C, Hu D, Fish J, Klein O, et al. (2013) Fgf8 dosage determines midfacial integration and polarity within the nasal and optic capsules. Dev Biol 374: 185–197. [PubMed]
32. Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, et al. (2008) Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 142: 859–876. [PMC free article] [PubMed]
33. Marszalek B, Wojcicki P, Kobus K, Trzeciak WH (2002) Clinical features, treatment and genetic background of Treacher Collins syndrome. J Appl Genet 43: 223–233. [PubMed]
34. Kondrashov N, Pusic A, Stumpf CR, Shimizu K, Hsieh AC, et al. (2011) Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. Cell 145: 383–397. [PubMed]
35. Qu S, Tucker SC, Zhao Q, deCrombrugghe B, Wisdom R (1999) Physical and genetic interactions between Alx4 and Cart1. Development 126: 359–369. [PubMed]
36. Lohnes D, Mark M, Mendelsohn C, Dolle P, Dierich A, et al. (1994) Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 120: 2723–2748. [PubMed]
37. Morrison-Graham K, Schatteman GC, Bork T, Bowen-Pope DF, Weston JA (1992) A PDGF receptor mutation in the mouse (Patch) perturbs the development of a non-neuronal subset of neural crest-derived cells. Development 115: 133–142. [PubMed]
38. Soriano P (1997) The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691–2700. [PubMed]
39. Murray JC, Daack-Hirsch S, Buetow KH, Munger R, Espina L, et al. (1997) Clinical and epidemiologic studies of cleft lip and palate in the Philippines. Cleft Palate Craniofac J 34: 7–10. [PubMed]
40. Zarbalis K, Wurst W (2000) Expression domains of murine ephrin-A5 in the pituitary and hypothalamus. Mech Dev 93: 165–168. [PubMed]
41. International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789–796. [PubMed]
42. Horvath S, Xu X, Laird NM (2001) The family based association test method: strategies for studying general genotype–phenotype associations. Eur J Hum Genet 9: 301–306. [PubMed]
43. Dudbridge F (2008) Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. hum hered 66: 87–98. [PMC free article] [PubMed]
44. Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365–386. [PubMed]
45. Mansilla MA, Cooper ME, Goldstein T, Castilla EE, Lopez Camelo JS, et al. (2006) Contributions of PTCH gene variants to isolated cleft lip and palate. Cleft Palate Craniofac J 43: 21–29. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science